Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study

Fig. 4

Survival according to SMD among chemotherapy responders vs. non-responders. Among responders (CR/PR), OS was not associated with SMD status (a). Among non-responders (SD/PD), patients with low SMD showed poorer OS than those with high SMD (median, 5.6 vs. 7.4 months, P = 0.006) (b). Among non-responder, patients with low SMD also showed poorer survival after progression at 8 weeks of initiation of chemotherapy than their high SMD-group counterparts (2.2 vs. 3.4 months, P = 0.004) (c)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us